Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, Goletti D; SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Cantini F, et al. Among authors: prignano f. Autoimmun Rev. 2015 Jun;14(6):503-9. doi: 10.1016/j.autrev.2015.01.011. Epub 2015 Jan 21. Autoimmun Rev. 2015. PMID: 25617816 Free article. Review.
Tuberculosis reactivation risk in dermatology.
Pescitelli L, Ricceri F, Prignano F. Pescitelli L, et al. Among authors: prignano f. J Rheumatol Suppl. 2014 May;91:65-70. doi: 10.3899/jrheum.140104. J Rheumatol Suppl. 2014. PMID: 24789002 Review.
Measuring psoriatic disease in clinical practice. An expert opinion position paper.
Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I, Scarpa R, Spadaro A, Atzeni F, Narcisi A, Ricceri F, Sarzi-Puttini P. Lubrano E, et al. Among authors: prignano f. Autoimmun Rev. 2015 Oct;14(10):864-74. doi: 10.1016/j.autrev.2015.05.010. Epub 2015 May 27. Autoimmun Rev. 2015. PMID: 26025585 Review.
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Milla M, Prignano F, Annese V, Romagnani S, Maggi E, Matucci A; ABIRISK Consortium. Vultaggio A, et al. Among authors: prignano f. Clin Exp Immunol. 2016 Dec;186(3):364-372. doi: 10.1111/cei.12858. Epub 2016 Oct 26. Clin Exp Immunol. 2016. PMID: 27569750 Free PMC article.
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A. Nencini F, et al. Among authors: prignano f. J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):2065-2072.e2. doi: 10.1016/j.jaip.2018.04.007. Epub 2018 Apr 13. J Allergy Clin Immunol Pract. 2018. PMID: 29660428
215 results